CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CoDon AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CoDon AG
Warthestrasse 21
Phone: +49 332843460p:+49 332843460 TELTOW, 14513  Germany Ticker: CNWCNW
Filed for Insolvency on 7/26/2022
On 7/26/2022, CoDon AG today filed an application with the District Court of Leipzig to open Insolvency Proceedings due to impending insolvency. The Insolvency Proceedings are to be conducted in the form of Self-Administration.
On 8/2/2022, the District Court of Leipzig ordered the Self-Administration Procedure as requested and appointed Mr. Rüdiger Wienbergo of HWW Hermann Wienberg Wilhelm as Provisional Administrator.
On 1/20/2023, it was announced that ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of CoDon AG. The Company will operate in the form of CO.DON GmbH.
Business Summary
CoDon AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company develops, produces, and distributes autologous cell therapies for the minimally invasive repair of cartilage defects, it manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal cartilage defects, lumbar disc herniation, non-union fractures, and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. It also offers biopsy, cultivation, transplantation, rehabilitation and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
3842 Orthopedic, prosthetic, and surgical appliances and supplies
3843 Dental equipment and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board ThommyStaehlin 4/26/2022 11/29/2005
Independent Deputy Chairwoman of the Supervisory Board BarbaraSickmueller 4/26/2022 6/18/2010
Member of the Management Board TilmannBur 56 12/31/2020 6/1/2019
3 additional Officers and Directors records available in full report.

Business Names
Business Name
0Q37
CNW
CNWK
co.don AG
CoDon GmbH

General Information
Number of Employees: 134 (As of 12/31/2021)
Outstanding Shares: 26,723,248 (As of 8/31/2022)
Shareholders: 300
Stock Exchange: FRA
Fax Number: +49 3328434643


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, October 28, 2024